In this episode of Precision and Progress: Radiotherapy in Oncology, Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, co-hosted a discussion with Valentina Bonev, MD, DABS, FACS, FSSO, about the interplay between surgery and radiation in breast cancer care.

Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.

Dr Vulsteke discusses the FDA approval of enfortumab vedotin-ejfv plus pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer.

Drs Rotow and Woodard talk through recent updates to the perioperative non–small cell lung cancer treatment paradigm.

Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.

Dr Phull reviews findings from a translational study that longitudinally profiled the fecal microbiome of patients with newly diagnosed myeloma.

Drs Kim and Malhotra discuss factors that make IB6 unique vs other NSCLC biomarkers and the study of sigvotatug vedotin in previously treated NSCLC.

Drs Armstrong and Tawagi highlight chronic lymphocytic leukemia updates from the 2025 ASH Annual Meeting.

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

Drs Tiesi, Scholer, Golas, and Pletcher discuss the use of hepatic artery infusion in colon cancer and liver cancer management.

Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

Drs Tiesi, Scholer, Golas, and Pletcher discussed the use of PIPAC, a minimally invasive regional cancer therapy, in patients with peritoneal cancers.

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.

In today’s episode, we had the pleasure of speaking with Daniel Spratt, MD, chair and professor in the Department of Radiation Oncology at Case Western Reserve University School of Medicine and a member of the Case Comprehensive Cancer Center in Cleveland, Ohio. Dr Spratt discussed key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer, including how advances in molecular imaging, evolving systemic therapy options, and the integration of next-generation androgen deprivation therapy (ADT) are reshaping treatment recommendations across localized, recurrent, and advanced disease settings.

In today’s episode,filmed live at the 43rd Annual CFS Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with breast cancer experts Kamel Abou Hussein, MD, and Victoria Rizk, MD, about the rapidly evolving therapeutic landscape in breast cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Abou Hussein is co-director of the Janet Knowles Breast Cancer, director of Breast Medical Oncology, and director of Breast Cancer Clinical Trials at Cooper University Health Care; as well as an assistant professor of medicine at Cooper Medical School of Rowan University in Camden, New Jersey. Dr Rizk is a medical oncologist at Tampa General Hospital Cancer Institute in Florida.